ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologics"

  • Abstract Number: 323 • 2013 ACR/ARHP Annual Meeting

    Safety Of Ustekinumab From The Placebo-Controlled Periods Of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs

    Iain B. McInnes1, Kim Papp2, Lluis Puig3, Kristian Reich4, Christopher T. Ritchlin5, Bruce Strober6, Proton Rahman7, Arthur Kavanaugh8, Alan M. Mendelsohn9, Michael Song10, Daphne Chan10, Yaung-Kaung Shen10, Shu Li10 and Alice B. Gottlieb11, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Probity Research, Waterloo, ON, Canada, 3Universitat Autònoma de Barcelona, Barcelona, Spain, 4SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany, 5Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 6University of Connecticut, Farmington, CT, 7Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 8University of California, San Diego, La Jolla, CA, 9Immunology, Janssen Research & Development, LLC., Spring House, PA, 10Janssen Research & Development, LLC., Spring House, PA, 11Tufts Medical Center, Boston, MA

    Background/Purpose:   To describe the short-term safety experience of UST during the double-blind, PBO-controlled portion of the PsA & PsO clinical developmental programs. Methods: Safety…
  • Abstract Number: 2325 • 2013 ACR/ARHP Annual Meeting

    Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized, Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy

    Josef S. Smolen1, Jonathan Kay2, Robert Landewé3, Eric L. Matteson4, Norman B. Gaylis5, Jürgen Wollenhaupt6, Frederick T. Murphy7, Chenglong Han8, Timothy A. Gathany8, Stephen Xu9, Yiying Zhou10, Elizabeth C. Hsia9 and Mittie K. Doyle9, 1Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, 3Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, 4Rheumatology, Mayo Clinic, Rochester, MN, 5Arthritis & Rheumatic Disease Specialties, Aventura, FL, 6Schön Klinik Hamburg-Eilbek, Hamburg, Germany, 7Altoona Ctr for Clinical Research, Duncansville, PA, 8Janssen Global Services, LLC., Malvern, PA, 9Janssen Research & Development, LLC., Spring House, PA, 10Biostatistics, Janssen Research & Development, LLC., Spring House, PA

    Background/Purpose: GO-AFTER was the first multicenter, randomized, placebo (PBO)-controlled trial of the safety/efficacy of an anti-TNFα agent, GLM, in pts with active RA despite prior…
  • Abstract Number: 1534 • 2013 ACR/ARHP Annual Meeting

    Safety and Efficacy Of Golimumab, a Human Anti-Tumor Necrosis Factor Monoclonal Antibody Injected Subcutaneously Every 4 Weeks, In Chinese Patients With Active Ankylosing Spondylitis: 1-Year Results Of a Phase 3, Randomized, Placebo-Controlled Study

    Chunde Bao1, Feng Huang2, Muhammad Asim Khan3, Kaiyin Fei4, Zhong Wu4, Yanli Zhuang4, Timothy A. Gathany5, Chenglong Han5 and Elizabeth C. Hsia4, 1Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, 2Dept of Rheumatology, Chinese PLA General Hospital, Beijing, China, 3Medicine/ Rheumatology, Case Western Reserve University Hospital, Cleveland, OH, 4Janssen Research & Development, LLC., Spring House, PA, 5Janssen Global Services, LLC., Malvern, PA

    Background/Purpose: A multicenter, randomized, placebo (PBO)-controlled study of golimumab (GLM) was performed in Chinese pts with ankylosing spondylitis (AS). To assess efficacy and safety of…
  • Abstract Number: 800 • 2013 ACR/ARHP Annual Meeting

    A Strategy For Selecting Individuals With RA For Reduction Of Anti-TNF Therapy Using Combined Clinical and Ultrasound Assessment

    Christopher R. Holroyd1,2, Brian Davidson3, Sarah Bennett3, David Waghorn3, Caron Underhil3, Cyrus Cooper2, Antonia Calogeras3, Elaine M. Dennison4, Nicholas C. Harvey5, Ray Armstrong3, Stephan Gadola6 and Christopher J. Edwards7,8, 1Rheumatology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, 2MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, 3University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, 4MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, 5University of Southampton, MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, 6University of Southampton, Southampton, United Kingdom, 7NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, 8University of Southampton, Southampton, United Kingdom

    Background/Purpose: Reducing the dose of biological therapy may be possible for patients with rheumatoid arthritis (RA) who have achieved remission or low disease activity (LDA). …
  • Abstract Number: 324 • 2013 ACR/ARHP Annual Meeting

    Long-Term Safety Of Ustekinumab: 5 Years Of Follow-Up From The Psoriasis Clinical Development Program Including Patients With Psoriatic Arthritis

    Kim Papp1, Christopher E.M Griffiths2, Kenneth B. Gordon3, Mark Lebwohl4, Philippe O. Szapary5, Yasmine Wasfi5, Daphne Chan5, Yaung-Kaung Shen5, Vincent Ho6, Pierre-Dominique Ghislain7, Bruce Strober8 and Kristian Reich9, 1Probity Research, Waterloo, ON, Canada, 2Dermatology Centre, University of Manchester, Manchester, United Kingdom, 3Feinberg School of Medicine, Northwestern University, Chicago, IL, 4Mount Sinai Medical Center, New York, NY, 5Janssen Research & Development, LLC., Spring House, PA, 6University of British Columbia, Vancouver, BC, Canada, 77. Cliniques Universitaires Saint-Luc, Université Catholique de Louvain,, Brussels, Belgium, 8University of Connecticut, Farmington, CT, 9SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany

    Background/Purpose: Ustekinumab(UST) is approved for moderate-to-severe psoriasis (PsO), and is currently in Phase 3 development for psoriatic arthritis (PsA). We report the long-term safety experience…
  • Abstract Number: 2283 • 2013 ACR/ARHP Annual Meeting

    The Evolving Use Of Biologic Monotherapy In Rheumatoid Arthritis and Its Impact On Patient Outcomes

    Laurent Chanroux, Katrina Johnson and Joan Casellas, Therapy Watch, The Research Partnership, London, United Kingdom

    Background/Purpose: The aim of our study is to understand whether the use of biologic monotherapy among rheumatoid arthritis (RA) patients is increasing and whether this…
  • Abstract Number: 1482 • 2013 ACR/ARHP Annual Meeting

    Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice

    Gabriela Ávila1, Sara Marsal1, Arnald Alonso1, Carolina Diaz2, Estefanía Quesada-Masachs2, María López-Lasanta1 and Isabel Acosta3, 1Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 2Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain, 3Vall d'Hebron Hospital Research Institute, Barcelona, Spain

    Background/Purpose: The wide use of biological therapies (BTs) has largely modified the therapeutic approach in Chronic Inflammatory Arthritis (CIA). These relatively new drugs have different…
  • Abstract Number: 717 • 2013 ACR/ARHP Annual Meeting

    Patients With Rheumatoid Arthritis Have Impaired Candida Albicans Specific Th17 Responses But Preserved Oral Candida Albicans Protective Immunity

    Shrinivas Bishu1, E. Wern Su2, Erich Wikerson3, Donald M. Jones4, Kelly A. Reckley5, Sarah L. Gaffen3 and Marc C. Levesque6, 1Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, PA, 2Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 3Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 4Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 5Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 6Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA

    Background/Purpose: Rheumatoid arthritis (RA) patients are susceptible to infections, even after controlling for the effects of medications.  Recent data suggest an important role for the…
  • Abstract Number: 292 • 2013 ACR/ARHP Annual Meeting

    Body Surface Area-Based Dosing Approach Produced Comparable Golimumab Exposure Across Different Age Ranges After Subcutaneous Administration Of Golimumab In Pediatric Patients With Juvenile Idiopathic Arthritis

    Jocelyn H. Leu1, Alan M. Mendelsohn2, Joyce Ford1, Hugh M. Davis1 and Zhenhua Xu1, 1Janssen Research & Development, LLC., Spring House, PA, 2Immunology, Janssen Research & Development, LLC., Spring House, PA

    Background/Purpose:   To evaluate the pharmacokinetics (PK) of body surface area (BSA)-adjusted dosing of SC golimumab 30 mg/m2 every 4 weeks (q4w) + methotrexate (MTX)…
  • Abstract Number: 2269 • 2013 ACR/ARHP Annual Meeting

    Patient Reported Pain: A Predictor Of Outcomes In Rheumatoid Arthritis From The Consortium Of Rheumatology Researchers Of North America Registry

    Dimitrios A. Pappas1, Chitra K. Karki2, Chin Lee3, George W. Reed4, Ping He5 and Sarah Al Sawah3, 1Columbia University, New York, NY, 2Corrona, LLC., Southborough, MA, 3Eli Lilly and Company, Indianapolis, IN, 4CORRONA, Inc., Southborough, MA, 5UMASS Medical School, Worcester, MA

    Background/Purpose:  Pain is a hallmark of rheumatoid arthritis (RA). The extent to which patient reported pain in RA is related to patterns of biologic treatment…
  • Abstract Number: 1483 • 2013 ACR/ARHP Annual Meeting

    Physician and Patient Characteristics Associated With The Decision To Treat Rheumatoid Arthritis Patients With Biologic Monotherapy In Usual Care Settings

    Mariely Nieves-Plaza1, Heather Eng2, Ilinca D. Metes3, Ashwini Shewede4, Stephen R. Wisniewski2, Ani John4 and Marc C. Levesque5, 1Clinical And Translational Science Institute, Univeristy of Pittsburgh, Pittsburgh, PA, 2Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 3Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, 4Genentech Inc., South San Francisco, CA, 5Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA

    Background/Purpose: Approximately 30% of rheumatoid arthritis (RA) patients treated with a biologic, receive the biologic as monotherapy i.e. without concomitant oral disease modifying anti-rheumatic drugs…
  • Abstract Number: 522 • 2013 ACR/ARHP Annual Meeting

    Abatacept Reduces Disease Activity In Early Primary Sjögren’s Syndrome:One Year Results From a Phase II Open-Label Study

    PM Meiners1, A Vissink2, Fkl Spijkervet3, EA Haacke4, WH Abdulahad5, E Brouwer5, MG Huitema5, N Sillevis Smitt-Kamminga6, FGM Kroese7, S Arends5 and H Bootsma5, 1Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 3Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, Netherlands, 4Pathology, University Medical Center Groningen, Groningen, Netherlands, 5Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 6Opthalmology, University Medical Center Groningen, Groningen, Netherlands, 7Rheumatology and clinical immunology, University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Traditional DMARDs have limited effects in primary Sjögren's (pSS) patients. B cell depletion therapy with rituximab showed efficacy, but had some side-effects. T and…
  • Abstract Number: 193 • 2013 ACR/ARHP Annual Meeting

    Physician Variability In Rheumatoid Patients Not Receiving Biologics Or Non-Biologic Dmards: Implications For Quality Reporting

    Dimitrios A. Pappas1, Lang Chen2, Leslie R. Harrold3, George W. Reed4, Joel M. Kremer5, Jeffrey D. Greenberg6 and Jeffrey R. Curtis7, 1Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, 2Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3University of Massachusetts Medical School, Worcester, MA, 4Corrona, LLC., Southborough, MA, 5Center for Rheumatology, Albany Medical College, Albany, NY, 6Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, 7University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL

    Background/Purpose: Current quality of care guidelines recommend that all patients with Rheumatoid Arthritis (RA) be treated with biologic and/or non-biologic (nb) DMARDs. However, some RA…
  • Abstract Number: 2225 • 2013 ACR/ARHP Annual Meeting

    COVA322: A Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor With Excellent Pharmacokinetic Properties In Mice and Cynomolgus Monkeys

    Mathias Locher, Dragan Grabulovski, Isabella Attinger-Toller, Susann Koenig-Friedrich, Ulrike von der Bey and Julian Bertschinger, Covagen AG, Schlieren, Switzerland

    Background/Purpose: The generation of bispecific antibody molecules with excellent biophysical and pharmacokinetic properties has been a challenging task in the past. We present here COVA322,…
  • Abstract Number: 1473 • 2013 ACR/ARHP Annual Meeting

    Anti-Tumor Necrosis Factor α Therapy (Etanercept) Plus Methotrexate Lowers Serum Amyloid A Levels To a Greater Extent Than Triple Oral Disease Modifying Anti-Rheumatic Drug Therapy In Early Rheumatoid Arthritis Subjects

    Ilinca D. Metes1, Douglas W. Chew1, Aarat M. Patel1, G.K. Balasubramani2, S. Louis Bridges Jr.3, Jeffrey R. Curtis4, Stephen R. Wisniewski2, Larry W. Moreland5 and Marc C. Levesque6, 1Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, 2Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 3Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 6Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Amyloidosis is often due to an underlying inflammatory disorder, such as rheumatoid arthritis (RA), with organ deposition of serum amyloid A (SAA).  Oral disease…
  • « Previous Page
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology